Shares of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) rose 4.2% during mid-day trading on Monday . The company traded as high as $6.93 and last traded at $6.87, with a volume of 210,942 shares trading hands. The stock had previously closed at $6.59.

FOMX has been the subject of a number of research reports. Zacks Investment Research lowered Foamix Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, May 4th. Guggenheim reiterated a “buy” rating and issued a $10.00 price target on shares of Foamix Pharmaceuticals in a report on Tuesday, May 10th.

The firm has a 50 day moving average price of $6.58 and a 200-day moving average price of $6.62. The company’s market capitalization is $206.32 million.

Foamix Pharmaceuticals (NASDAQ:FOMX) last released its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.08. Equities research analysts forecast that Foamix Pharmaceuticals Ltd. will post ($0.89) EPS for the current year.

A hedge fund recently raised its stake in Foamix Pharmaceuticals stock. Tekla Capital Management LLC raised its position in Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) by 6.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 652,145 shares of the specialty pharmaceutical company’s stock after buying an additional 38,568 shares during the period. Tekla Capital Management LLC owned 2.13% of Foamix Pharmaceuticals worth $5,289,000 as of its most recent filing with the SEC.

Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.